Biocept Inc. (BIOCQ)

Biocept Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2022	2021	2020	2019	2018
Revenue	25.86	61.25	27.46	5.53	3.25
Revenue Growth (YoY)	-57.78%	123.04%	396.71%	70.09%	-35.87%
Cost of Revenue	28.44	37.76	21.34	10.98	10.05
Gross Profit	-2.58	23.49	6.12	-5.45	-6.8
Selling, General & Admin	23.24	20.93	16.37	12.91	12.99
Research & Development	6.16	4.96	5.22	4.7	4.47
Operating Expenses	29.4	25.89	21.59	17.61	17.46
Operating Income	-31.98	-2.41	-15.47	-23.06	-24.26
Interest Expense / Income	0.32	0.29	0.24	0.25	0.31
Other Expense / Income	-0.09	-	2.1	1.83	-
Pretax Income	-32.21	-2.7	-17.81	-25.14	-24.57
Income Tax	-0.13	0.13	0	0	0
Net Income	-32.09	-2.82	-17.81	-25.14	-24.57
Preferred Dividends	0	0	0	0.12	0.64
Net Income Common	-32.09	-2.82	-17.81	-25.26	-25.21
Shares Outstanding (Basic)	1	0	0	0	0
Shares Outstanding (Diluted)	1	0	0	0	0
Shares Change	14.74%	24.74%	473.32%	638.38%	205.30%
EPS (Basic)	-56.70	-5.70	-45.00	-366.90	-2703.00
EPS (Diluted)	-56.70	-5.70	-45.00	-366.90	-2703.00
Free Cash Flow	-14.1	2.12	-20.65	-23.78	-22.5
Free Cash Flow Per Share	-24.94	4.30	-52.31	-345.36	-2412.28
Gross Margin	-9.99%	38.34%	22.30%	-98.56%	-209.26%
Operating Margin	-123.69%	-3.93%	-56.33%	-417.05%	-746.35%
Profit Margin	-124.09%	-4.61%	-64.86%	-456.89%	-775.56%
Free Cash Flow Margin	-54.51%	3.46%	-75.21%	-430.21%	-692.26%
EBITDA	-29.7	0.23	-16.57	-24.11	-23.46
EBITDA Margin	-114.86%	0.37%	-60.34%	-436.18%	-721.71%
Depreciation & Amortization	2.2	2.64	1	0.77	0.8
EBIT	-31.9	-2.41	-17.57	-24.89	-24.26
EBIT Margin	-123.35%	-3.93%	-63.99%	-450.17%	-746.35%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).